QNTM is trading 6.3% up at $3.66 in pre-market action, rebounding from a recent pullback following a significant clinical milestone.
- Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway enrollment mark.
- Preliminary PET imaging results for the Lucid-MS candidate are encouraging, highlighting the drug's potential and drawing fresh investor attention to the volatile small-cap biotech.